With the increasing use of antiretroviral (ARV) drugs to prevent mother-to-child transmission of human immunodeficienc virus (HIV), large numbers of infants are exposed, with possible consequent toxicity.
countries since 1994, when Pediatric AIDS Clinical Trials Group protocol 076 showed that administration of zidovudine to the HIV-infected woman during pregnancy and labor and to her newborn reduced the risk of mother-to-child HIV transmission by nearly 70% [1] . Subsequently, it was recognized that the use of combination antiretroviral (ARV) drug regimens during pregnancy could further reduce transmission [2] . Current recommendations for the prevention of mother-to-child transmission in the United States include the use of ARV combination therapy during pregnancy for women with HIV RNA loads 11000 copies/mL, with the use of zidovudine prophylaxis alone restricted to women with HIV RNA loads !1000 copies/mL [3] . Although mother-to-child transmission in the United States has dramatically decreased, from 25% to !2% [2] , this significan advance entails the in utero and neonatal exposure of many infants to у1 drug of unknown toxicity.
Although data regarding the short-term safety of exposure to ARV drugs for uninfected infants have been reassuring [4] [5] [6] , there is limited information about long-term effects. Preclinical data have indicated that some ARV drugs, particularly those in the nucleoside-analogue reverse-transcriptase inhibitor (NRTI) class, may be associated with mitochondrial dysfunction [7, 8] , and it has been suggested that some infants with in utero or neonatal exposure to these drugs may have laboratory or clinical signs of mitochondrial dysfunction. The French Perinatal Cohort Study Group studied 2644 uninfected HIV-and ARV-exposed children, and they reported an 18-month incidence of clinical symptoms (primarily neurologic) of mitochondrial dysfunction of 0.26% and a mortality incidence of 0.07% [9] . The same group also reported an increased risk of simple febrile seizures during the firs 18 months of life and persistently lower (but clinically insignificant neutrophil, lymphocyte, and platelet counts in infants associated with in utero NRTI exposure [10, 11] . Although these clinical abnormalities and mortality finding have not been duplicated to date in other cohorts in the United States and Europe [12, 13] , the European Collaborative Study reported similar hematologic abnormalities in uninfected infants with in utero or neonatal ARV exposure [14, 15] .
We report here an analysis of data from the Women Infant Transmission Study (WITS), a longitudinal cohort of HIV-infected mothers and their infants from the United States and Puerto Rico that explores the effect of perinatal exposure to ARV drugs on hematologic and lymphocytic parameters in HIV-uninfected infants and children during the firs 2 years of life.
SUBJECTS AND METHODS

WITS.
The present analysis was conducted using retrospective data obtained from mother-infant pairs enrolled in the WITS cohort during 1989-2004. WITS is a prospective observational, multicenter study that was established in 1989. The study population is recruited from 6 sites in the United States and Puerto Rico (Boston and Worcester, Massachusetts; Brooklyn and Manhattan, New York; Chicago, Illinois; Houston, Texas; and San Juan, Puerto Rico). HIV-infected women were recruited during pregnancy and monitored at regular intervals throughout pregnancy, delivery, and the postpartum period. Data obtained from mothers include the use of ARV drugs before and during pregnancy, hard drug use, and maternal medical complications. Their children are monitored at regular intervals from birth, and clinical and laboratory parameters are recorded at regular intervals. Flow-cytometric analysis was performed and controlled for quality as described elsewhere [16, 17] . Informed consent was obtained from all women before their participation in the study. All research activities were approved by institutional review boards at each local site, in accordance with federal guidelines and regulations for the conduct of research involving human subjects.
Study population. Data from singleton pregnancies resulting in HIV-exposed but uninfected infants were analyzed. An infant was define as HIV-uninfected if 2 HIV virologic tests were negative at or after age 1 month and at or after age 4 months or if 1 HIV serologic test was negative after age 18 months. Perinatal maternal and infant ARV use was categorized as "no ARV" (no ARV use during pregnancy or by the infant after birth), and "any ARV" (ARV use during pregnancy and/ or by the infant). The any-ARV group consisted of 2 large groups: ARV monotherapy (1 antiretroviral drug used during pregnancy and/or by the infant) and ARV combination therapy (2 ARVs or highly active ARV therapy used during pregnancy and/or by the infant). The ARV combination therapy group was further divided into 2 subgroups: persons who received protease inhibitors (PIs) and persons who did not. In general, as in previous WITS analyses, mother-infant pairs in the no-ARV group were from before 1994, those in the ARV monotherapy group were from 1994 to 1997, and those in the ARV combination therapy group were from subsequent years [2] .
Hard drug use during pregnancy was define as the use of cocaine, heroin/opiates, methadone, and/or injection drugs as ascertained by self-report and/or positive urine toxicologic results at prenatal or delivery visits [18] . Infants were evaluated and blood was collected at age 0-7 days (usually within the firs 48 h of life), at ages 6-10 days and 1 and 2 months, and at 2-6-month intervals thereafter. For most analyses, laboratory data were divided into 2 groups: data from blood collected during the firs 2 months of life (0-7 days and 2 months) and data from blood collected from age 6-24 months (6, 12, 18, and 24 months). Infants who had laboratory values for at least 1 study visit were included in the analysis. The variables evaluated included hemoglobin concentration and platelet, neutrophil, total lymphocyte, and CD4 + and CD8 + cell counts. Statistical analysis. Descriptive statistics were used to characterize the study population. For continuous variables, means and ranges were reported; for discrete variables, frequencies and percentages were reported. Multivariate regression analysis with robust variance (general estimating equations) was used to assess the association between perinatal exposure to ARV drugs and the define hematologic variables. The models were adjusted for age, preterm birth (!37 weeks of gestation), maternal hard drug use [18] , race/ethnicity, mode of delivery, maternal Centers for Disease Control and Prevention (CDC) clinical classification infant's birth weight, infant's sex, and maternal CD4
+ cell count at delivery. The associations were examined during 2 periods of life: from birth until age 2 months and from age 6-24 months. SAS software (version 8.2; SAS Institute) was used to perform statistical analysis. Two-tailed P values are reported.
RESULTS
Population characteristics.
A total of 2171 HIV-infected mothers (table 1) and their HIV-exposed, uninfected children (table 2) were included in the analysis. Among participant mother-infant pairs, 351 were classifie as having received no ARV drugs, and 1820 were classifie as having received any ARV drugs. The latter group was divided into 803 pairs for whom exposure was to ARV monotherapy (91% zidovudine) and 1017 pairs for whom exposure was to ARV combination therapy. Within the any-ARV group, there were 18 mothers who were not themselves treated but whose infants received 4-6 weeks of zidovudine alone ( ) or ARV combination n p 14 therapy ( ) after birth. The group that received ARV comn p 4 bination therapy was further divided into ARV combination therapy with ( ) and without ( ) PIs. Of women n p 676 n p 341 who received ARV combination therapy that included PIs, 90 also received a nonnucleoside reverse-transcriptase inhibitor (NNRTI); of women who received ARV combination therapy that did not include PIs, 129 received an NNRTI. The racial and ethnic distribution of HIV-infected women was similar in the no-ARV and any-ARV groups. There were significan differences between the no-ARV group and the any-ARV group in the proportion of women using hard drugs during pregnancy, CDC clinical classification mean CD4 + cell count at delivery, and proportion of women with CD4 + cell counts !200 cells/mm 3 at delivery (4.6% vs. 14.2%, respectively). As shown in table 2, the gestational age of ARV-exposed children was slightly but significantl lower than that of ARVunexposed infants (38.1 vs. 38.5 weeks), possibly because of more-frequent delivery via cesarean section after 1994. As mentioned above, all but a few of the ARV-unexposed infants were born before 1994. Of the 1687 infants who received ARV prophylaxis, 1536 (91.05%) received zidovudine alone.
Overall results. + cell counts) (data not shown). Further analyses controlled for these variables. Table 3 summarizes the multivariate analysis of various hematologic parameters in infants exposed and not exposed to ARV drugs, with separate comparisons of any, single, and a combination of ARV drugs with no ARV drugs. Hemoglobin concentration and platelet, neutrophil, total lymphocyte, and CD4 + cell counts were significantl lower in the any-ARV group than in the no-ARV group during the firs 2 months of life. The CD8 + cell count was borderline significantl lower in infants exposed to ARV drugs. By age 6-24 months, there were no longer significan differences in hemoglobin concentration and neutrophil count between ARV exposure groups, although the neutrophil count in infants exposed to ARV drugs remained lower than that in infants not exposed to ARV drugs (regression coefficient Ϫ152 cells/mm 3 ; ). However, platelet, total P p .05 lymphocyte, CD4 + , and CD8 + cell counts all remained significantly lower in infants exposed to ARV drugs than in infants not exposed to ARV drugs through age 24 months.
In infants through age 2 months, exposure to ARV combination therapy was associated with greater differences in neutrophil, lymphocyte, CD4 + , and CD8 + counts than exposure to a single ARV drug. For example, the difference in neutrophil count between the no-ARV and ARV monotherapy groups was Ϫ321 cells/mm 3 , whereas the difference between the no-ARV and ARV combination therapy groups was Ϫ548 cells/mm 3 ; the corresponding values for lymphocytes were Ϫ418 and Ϫ568 cells/mm 3 ; those for CD4 + cell counts were Ϫ136 and Ϫ183 cells/mm 3 ; and those for CD8 + cell counts were Ϫ33 and Ϫ115 cells/mm 3 . However, in infants age 6-24 months, with the exception of CD8 + cell count, there was little difference between decreases in infants in the ARV monotherapy groups, compared with those in the ARV combination therapy group. We also analyzed the impact of exposure to ARV combinations with PIs, compared with ARV combinations without PIs. There was remarkably little difference between these groups, with the sole exception of an apparent minor platelet-sparing effect of PI exposure that was evident both in infants 0-2 months old and those 6-24 months old ( and .02, respectively; data not P p .006 shown).
The effect of maternal immune status (CD4 + cell count at delivery !200, 200-500, or 1500 cells/mm 3 ) on infant hematologic parameters was also examined. In the multivariate models, a maternal CD4 + cell count !200 cells/mm 3 was significantl associated with a lower infant CD4 + cell count in both age groups: 0-2 months (Ϫ169 cells/mm 3 ;
) and 6-24 months (Ϫ183 P p .03 cells/mm 3 ;
) . P p .02 Progression of hematologic parameters over time. Figure  1A -1F shows the changes in hematologic parameters and lymphocyte subsets between birth and age 24 months. The figu e illustrates several points. First, the differences in hemoglobin concentration and neutrophil count, although statistically significant were minimal. Second, the differences in platelet, total lymphocyte, CD4 + , and CD8 + cell counts between ARV-unexposed and -exposed infants were significan at most visits throughout the period of study.
Number of infants with у1 event of clinically relevant hematologic abnormalities, by ARV exposure status. We evaluated the incidence of clinically significan laboratory abnormalities among the various ARV exposure groups. Clinically significan abnormalities were define as grade у3 toxicities in the Division of AIDS pediatric toxicity tables. These thresholds included hemoglobin concentration !7 g/dL, platelet count range, and the proportion of infants with у1 occurrence of these values did not differ significantl among the various ARV exposure groups.
DISCUSSION
These data from WITS, a large cohort study in the United States, demonstrate that several hematologic parameters are lower in HIV-exposed, uninfected infants with in utero and/ or neonatal exposure to ARV drugs, although these differences are small and appear to be clinically insignificant The hematologic effects of exposure to ARV drugs observed during the firs 2 months of life could be secondary to the ongoing exposure to ARV drugs given to the infant during the firs 6 weeks of life to prevent the transmission of HIV. However, although the difference in hemoglobin concentration resolved and that in neutrophil count became insignifican after age 2 months, significan differences persisted for platelet, lymphocyte, CD4 + , and CD8 + cell counts through age 24 months. Although exposure to ARV drugs in WITS was not randomized and there were changes over time in certain aspects of the study population and in the use of ARV drugs, the finding persisted even after we controlled for a number of parameters that have been shown to be associated with hematologic variables in other studies, such as maternal race/ethnicity, drug use, maternal CD4 + cell count at delivery, and infant gestational age, birth weight, sex, and age. Despite some differences in methodology and considerable differences in race/ethnicity, similar finding were reported from the French Perinatal Cohort Study Group and the European Collaborative Study [11, 14, 15] .
In the French Perinatal Cohort Study, HIV-uninfected infants with perinatal exposure to ARV drugs had significantl lower hemoglobin concentrations and platelet, neutrophil, total lymphocyte, CD4 + , and CD8 + cell counts than HIV-exposed infants without perinatal exposure to ARV drugs [10] . Although differences in hemoglobin concentrations resolved by age 2 months, the differences in the other hematologic parameters persisted through age 18 months. Those researchers reported that exposure to combination ARV drugs was associated with larger decreases than exposure to ARV monotherapy up to age 15 months. In addition, there was a negative relationship between the duration of treatment and neutrophil and lymphocyte counts, and a lower maternal CD4 + cell count at delivery was associated with lower infant lymphocyte and CD4 + cell counts.
In the European Collaborative Study, perinatal ARV exposure of HIV-exposed but uninfected children was associated with a reduced neutrophil count through age 8 years, regardless of race or sex; maternal immune status was only marginally associated with infant neutrophil counts in uninfected children [14] . In a separate analysis, the total lymphocyte count was significantl lower in uninfected infants with perinatal exposure to ARV drugs than in those without exposure to ARV drugs; the CD4 + cell count was lower only during the firs year of life, but the CD8 + count was reduced through age 8 years [15] . However, there was no significan difference between infants who were exposed to ARV drugs, compared with those who were not, in the incidence of lymphopenia, define as CDC immune stage р2. therapy had a stronger effect on total lymphocyte and CD8 + cell counts than exposure to ARV monotherapy, but the type of drug in the combination (e.g., PIs or NNRTIs) had no effect. Similar to the 2 other reports, our analysis of the WITS cohort found significantl lower platelet, total lymphocyte, CD4 + , and CD8 + cell counts in uninfected infants with exposure to ARV drugs than in those without exposure, and these differences persisted through age 24 months. Our data also demonstrate that the maternal immune status is associated with infant CD4 + cell counts. The mechanism by which maternal immune status might affect infant lymphocyte parameters is not clear. There have been suggestions that an immunodeficien mother may have defective transplacental transfer of hematopoietic cytokines, resulting in long-term consequences for the thymic output of CD4 + cells in the child [10, 15] . Additional studies are needed to elucidate this effect further. However, unlike the European studies, although exposure to ARV combination was associated in WITS with a stronger effect on these parameters during the firs 2 months of life, this potentiating effect of combination, compared with exposure to ARV monotherapy, persisted through age 24 months only for CD8 + cell count and not for platelet, total lymphocyte, or CD4 + cell counts. Additionally, in contrast to the French and European cohorts, in WITS, the effect of exposure to ARV drugs on neutrophil count did not remain significan after age 2 months. A recent study from Amsterdam compared hematologic parameters in 92 uninfected, HIV-exposed children, all but a few of whom had mothers who had received 3 ARV drugs during pregnancy and all of whom received combination zidovudine/ lamivudine therapy for the firs 4 weeks of life, with those in 75 children matched for gestational age, sex, and ethnicity who were born to HIV-uninfected women [19] . Like WITS and the other studies, differences in hemoglobin concentration were transient. Those researchers reported significantl lower neutrophil counts in the HIV-and ARV-exposed infants than in infants born to uninfected women through age 8 months. However, similar to the WITS analyses, these differences did not persist through age 20 months. By contrast, significan differences in platelet and absolute lymphocyte counts were not found in this considerably smaller cohort.
In vitro studies have demonstrated that ARV drugs can suppress the erythroid and myeloid cell lineages in bone marrow [20] [21] [22] [23] [24] . Cells cultured in the presence of zidovudine show a concentration-dependent inhibition of CD34 + progenitor proliferation in both myeloid and erythroid lineages, a decrease in mtDNA, and an increase in lactic acid [22] . In vitro studies of primary peripheral-blood lymphocyte cultures from individuals without HIV infection who are exposed to zalcitabine, didanosine, or stavudine have shown dose-and time-dependent mtDNA depletion accompanied by decreased cell proliferation, increased lactate production, and morphologic changes in mitochondria [23, 24] . It is known that NRTIs cross the placenta and achieve cordblood levels 50%-100% of those in maternal blood [3] . Hematopoietic progenitor cells from the fetus and neonate may be more sensitive to the myelotoxic effects of drugs. In a study that assessed the effect of zidovudine exposure in vitro, fetal erythroid progenitors were more severely inhibited than those from women of childbearing age, as manifested by a diminution in clone generation and in the number of normoblasts per erythroid clone and neutrophils per granulocyte clone [25] . This effect was secondary to an action on CD34 + progenitor cells, given that no effect was observed on the production of granulocyte colony-stimulating factor or erythropoietin. The precise mechanism of zidovudine's action on CD34 + cells is unclear. Additionally, HIV infection of the mother may by itself affect fetal hematologic precursor cells. Poirier et al. [26] measured mtDNA in cord blood and, at ages 1 and 2 years, peripheralblood mononuclear cells in children born to HIV-uninfected mothers, HIV-infected mothers who did not receive ARV drugs, and HIV-infected mothers who had received zidovudine during pregnancy. Infants born to HIV-infected women who did not receive ARV drugs had significan reductions in mtDNA that persisted up to age 2 years; mtDNA was even further depleted in infants born to HIV-infected mothers who had received zidovudine. Similarly, a study that compared HIV-exposed, uninfected infants born before 1994 who did not have perinatal exposure to ARV drugs with 72 infants born to HIV-uninfected women reported that CD4 + cell counts were persistently lower in HIV-exposed infants [27] .
ARV drugs are routinely prescribed during the second trimester, a time in the fetus when hepatic hematopoiesis is active, spleen development is occurring, and active lymphopoiesis, thymic education, and bone-marrow development are ongoing. The administration of ARVs during the critical window of hematopoiesis and lymphopoiesis may affect the generation of these precursors. The differences in hemoglobin concentrations in our patient population were no longer found in children 6-24 months old, which suggests a reversible insult in a system with ample recovery potential. Likewise, significan differences in neutrophil counts did not persist, which possibly reflect the fact that granulocytes are the last population to appear during development, are not formed in large numbers until after birth, and have brief life spans [28, 29] .
In conclusion, studies in different populations from Europe [11, 14, 15] and, now, the United States have indicated that perinatal exposure to ARV drugs is associated with minor decreases in hematologic parameters, most of which persist for at least the firs 2 years of life in uninfected, HIV-exposed infants. The studies vary in terms of which parameters remain persistently low. In all studies, hemoglobin concentrations re-turned to normal after ARV prophylaxis in infants was completed. However, in 2 of 3 European studies (but not WITS), significantl lower neutrophil counts persisted in children exposed to ARV drugs. Both of these European studies and WITS, but not the Amsterdam cohort, found small but persistent differences in lymphocyte parameters with exposure to ARV drugs, with a suggestion that exposure to ARV combination therapy may be associated with more-pronounced differences. Although these effects do not appear to have clinical significance they provide further evidence of the importance of the long-term follow-up of uninfected, HIV-and ARV-exposed children, as is recommended in the US Public Health Service Task Force guidelines for treatment of pregnant women with ARV drugs and the prevention of mother-to-child transmission [3] . Further studies are needed to better defin the mechanism of these effects and to evaluate whether they have clinical significanc in the long term. 
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